


Pociredir

Cat. No.:	HY-139400B
CAS No.:	2490674-02-5
Molecular Formula:	C ₂₂ H ₁₈ FN ₅ O ₂
Molecular Weight:	403.41
Target:	Histone Methyltransferase
Pathway:	Epigenetics
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Pociredir (FTX-6058) is a potent, selective and orally active small-molecule inhibitor of embryonic ectoderm development (EED) with K _D value of 0.163 nM. Pociredir can be used for the research of inflammatory or hemoglobinopathies, such as sickle cell disease (SCD) ^{[1][2]} .
In Vivo	Pociredir (QD, 5 mg/kg) reduces the H3K27me3 levels in the Townes mouse model of sickle cell disease (SCD) ^[1] . Pociredir (QD, 5 mg/kg) increases the levels of red blood cells and total hemoglobin, ameliorates hemolysis in the Townes mouse model of sickle cell disease (SCD) ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information, Vol. 36, No. 2, 2022.
- [2]. DavidMatson, et al. Ftx-6058 Induces Fetal Hemoglobin Production and Ameliorates Disease Pathology in Sickle Cell Mice. Blood (2021) 138 (Supplement 1): 2018.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA